Antiplatelet Thrombolysin (Anfibatide) Phase 1 Clinical Trial in Healthy Volunteers

Antiplatelet Drug Clinical Trial

Official title:
Phase I Clinical Trial of the Tolerance and Pharmacokinetics of Anfibatide in Health Volunteer

Status Suspended

Clinical Trial Summary

This is a phase 1, dose-escalation, and multidose study, aiming to investigate the tolerability, safety and pharmacokinetics of Anfibatate in healthy subjects. The study is divided into 2 intravenous single groups and 3 continuous administration groups. The dose of Anfibatate from 5 IU/60kg to 7 IU/60kg in intravenous single groups. The dose of Anfibatate from 0.002 IU/kg/h, 0.004 IU/kg/h to 0.008 IU/kg/h in continuous administration groups.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Antiplatelet Drug

Clinical Trial Details

NCT number	NCT04404790
Study type	Interventional
Source	Lee's Pharmaceutical Limited
Contact
Status	Suspended
Phase	Phase 1
Start date	September 2020
Completion date	May 2021

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04971356` - 1-month DAPT Plus 5-month Ticagrelor Monotherapy Versus 12-month DAPT in Patients With Drug-coated Balloon	N/A
Recruiting	`NCT06243133` - Pair Antiplatelet THerapy in Ischemic Stroke With Intracranial Artery Stenosis	Phase 4
Recruiting	`NCT06269432` - Precise Antiplatelet THerapy Guided by Platelet Aggregation Function in Acute Ischemic STROKE（PATH-STROKE）	Phase 4
Recruiting	`NCT05852197` - Effect of Anticoagulant Drug Intervention on Postoperative MALE and MACE in Patients With PAD